Investors & Media

Company Overview

LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder.

Press Releases News Insights

Featured Release

Data and Safety Monitoring Board Approves LyGenesis's Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration

The DSMB reviewed the safety, tolerability, and efficacy data from the trial's first cohort of four patients. Based on their review, the DSMB's recommendation to proceed highlights the safety and tolerability of LyGenesis's innovative approach to organ regeneration as they explore the ideal dose of their allogenic cell therapy to take into later stage clinical trials.

LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease

April 2, 2024 - LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has been dosed in their Phase 2a clinical trial evaluating their first-in-class allogenic regenerative cell therapy transplanted into patients' lymph nodes as a potential treatment for end-stage liver disease (ESLD).

LyGenesis and Imagine Pharma Announce Joint Research Collaboration to Develop Novel Cell Therapies for Patients with Type 1 Diabetes

April 11, 2023 - April 11, 2023 - The collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes

LyGenesis and Imagine Pharma Collaborate on allogeneic cell therapies for patients with type 1 diabetes

iTolerance and LyGenesis Announce a Joint Research Collaboration to Regrow Functioning, Ectopic Livers Without the Need for Immune Suppression

June 30, 2022 - The joint research collaboration will evaluate the potential of iTOL-201, the product candidate in development using iTolerance’s SA FasL microgel immune tolerance platform (iTOL-100) combined with LyGenesis’ liver cell therapy (LYG-LIV-100), to enable ectopic livers to be grown without the need or immune suppression.

LyGenesis Adds Inborn Errors of Metabolism, Orphan Pediatric Indications with Large Unmet Needs, to its Drug Development Pipeline

January 10, 2022 - Novel approach first aims to treat pediatric patients with Maple Syrup Urine Disease

LyGenesis Announces Four Peer-Reviewed Publications on its Organ Regeneration Technology

August 27, 2021 - Successful preclinical studies solidify the foundation for its first human clinical trial of a cell-based therapy to regenerate ectopic organs in lymph nodes

AgeX Therapeutics and LyGenesis Terminate Merger Negotiations

July 23, 2021 - LyGenesis will continue to advance its clinical-stage allogeneic cell therapy for patients with end stage liver disease, and advance its pipeline of preclinical cell therapies enabling pancreas, thymus, and kidney regeneration.